Background: Tau protein has been proposed as biomarker of axonal damage leading to irreversible neurological impairment in MS. CSF concentrations may be useful when determining risk of progression from ON to MS.
Objective: To investigate the association between tau protein concentration and 14-3-3 protein in the cerebrospinal fluid (CSF) of patients with monosymptomatic optic neuritis (ON) versus patients with monosymptomatic onset who progressed to multiple sclerosis (MS). To evaluate results against data found in a complete literature review.
Methods: A total of 66 patients with MS and/or ON from the Department of Neurology of Glostrup Hospital, University of Copenhagen, Denmark, were included. CSF samples were analysed for tau protein and 14-3-3 protein, and clinical and paraclinical information was obtained from medical records.
Results: The study shows a significantly increased concentration of tau protein in CSF from patients with relapsing–remitting MS and patients monosymptomatic at onset who progressed to MS, but interestingly no increased tau protein concentration in monosymptomatic ON. The concentration of tau protein was significantly correlated to Expanded Disability Status Scale score. No 14-3-3 protein was detected in any CSF sample.
Conclusions: The results of this study invite further exploration of the possible role of tau protein as a prognostic factor to predict progression from ON to MS in future studies.
SorensenTLFrederiksenJLBronnum-HansenHPetersenNC. Opticus neuritis as onset manifestation of multiple sclerosis: a nationwide, long-term study. Neurology1999; 53: 473–478.
2.
TrappBRansohoffRRudickR. Axonal pathology in multiple scleroses: relationship to neurologic disability. Curr Opin Neurol1999; 12: 295–302.
3.
TerziMBirinciACetinkayaEOnarMK. Cerebrospinal fluid total tau protein levels in patients with multiple sclerosis. Acta Neurol Scand2007; 115: 325–330.
4.
Bartosik-PsujekHStelmasiakZ. The CSF levels of total-tau and phosphotau in patients with relapsing-remitting multiple sclerosis. J Neural Transm2006; 113: 339–345.
5.
SüssmuthSReiberHTumaniH. Tau protein in cerebrospinal fluid (CSF): a blood-CSF barrier related evaluation in patients with various neurological diseases. Neurosci Lett2001; 300: 95–98.
6.
RostasyKWithutEPohlDLangePCiesielcykB. Tau, phospho-tau and S-100B in the cerebrospinal fluid of children with multiple sclerosis. J Child Neurol2005; 20: 822–825.
7.
BrettschneiderJMaierMArdaSClausASüssmuthSD. Tau protein level in cerebrospinal fluid is increased in patients with early multiple sclerosis. Mult Scler2005; 11: 261–265.
8.
ColluciMRoccagliataLCapelloENarcisoELatronicoNTabaltonM. The 14-3-3 protein in multiple sclerosis: a marker of disease severity. Mult Scler2004; 10: 477–481.
9.
Bartosik-PsujekHArchelosJ. Tau protein and 14-3-3 in the cerebrospinal fluid of patients with multiple sclerosis an correlate with intrathecal synthesis of IgG. J Neurol2004; 251: 414–420.
10.
BrettschneiderJPetzoldAJunkerAHTumami. Axonal damage markers in the cerebrospinal fluid of patients with clinically isolated syndromes improve predicting conversion to definite multiple sclerosis. Mult Scler2006; 12: 143.
11.
Martinez-YelamosASaizABasJHernandezJGrausF. Tau protein in cerebrospinal fluid: a possible marker of poor outcome in patients with early relapsing-remitting multiple sclerosis. Neurosci Lett2004; 363: 14–17.
12.
Martinez-YelamosARoviraASanchez-ValleRMartinez-YelamosSTintoreM. CSF 14-3-3 protein assay and MRI prognostic markers in patients with a clinically isolated syndrome suggestive of MS. J Neurol2004; 251: 1278–1279.
13.
Martinez-YelamosASaizASanchez-ValleRCasadoVRamonJM. 14-3-3 protein in the CSF as prognostic marker in early multiple sclerosis. Neurology2001; 57: 722–724.
14.
Jimenez-JimenezFZurdoJHernanzAMedina-AcebronSdeBustosFBarcenillaB. Tau protein concentrations in cerebrospinal fluid of patients with multiple sclerosis. Acta Neurol Scand2002; 106: 351–354.
15.
GuimarãresJCardosoMJSáMJ. Tau protein seems not to be a useful routine clinical marker of axonal damage in multiple sclerosis. Mult Scler2006; 12: 354–356.
16.
Hein (née Maier)KKöhlerADiemRSättlerMDemmerI. Biological markers of axonal degeneration in CSF and blood of patients with first event indicative of multiple sclerosis. Neurosci Lett2008; 436: 72–74.
17.
De SezeJPeoc’hKFerribyDStojkovicTLaplancheJVermerschP. 14-3-3 protein in the cerebrospinal fluid of patients with acute transverse myelitis and multiple sclerosis. J Neurol2002; 249: 626–627.
18.
ValisMTalabRStouracPAndrysCMasopustJ. Tau protein, phosphorylated tau protein and beta-amyloid 42 in the cerebrospinal fluid of multiple sclerosis patients. Neuroendocrinol Lett2008; 29: 971–976.
19.
Bartosik-PsujekHPsujekMJaworskiJStelmasiakZ. Total tau and S100b proteins in different types of multiple sclerosis and during immunosuppressive treatment with mitoxantrone. Acta Neurol Scand2011; 123: 252–256.
